ENA man has been diagnosed with early prostate cancer, and surgery or radiotherapy worries him because of possible incontinence and erectile problems. So he reads about a treatment «with ultrasound, without a scalpel» – HIFU. The method exists, but it does not suit everyone.
HIFU in Germany is offered by urology departments and specialised centres, mainly for selected cases of localised prostate cancer and, for other tumours, mostly within studies. Below: how it works, who it may suit, where it is still experimental, its risks and follow-up, and how treatment is arranged. Surgery, radiotherapy and active surveillance are covered on the prostate cancer treatment page.
How HIFU works
HIFU, high-intensity focused ultrasound, destroys tumour tissue with heat: many ultrasound beams are focused on one small point, like sunlight through a magnifying glass, and within seconds the tissue there heats up until the cells die. The tissue around the focus is largely spared. There is no incision and no radiation.
For the prostate, the probe is inserted into the rectum under general or spinal anaesthesia, and the doctor plans the treatment zone on ultrasound images, often fused with a prior MRI. The whole gland can be treated, or only the part with the tumour, which is called focal therapy; an option in between is treating the half that contains it.
HIFU for prostate cancer: who it may suit
Focal HIFU may suit a man whose tumour has not spread beyond the prostate and is low-risk or, within studies, intermediate-risk. The lesion should be clearly visible on multiparametric MRI, a scan with several sequences that shows suspicious areas, and confirmed by targeted plus systematic biopsy. These tests are described on the prostate cancer diagnostics page.
A second setting is a local recurrence in the prostate after radiotherapy, when surgery is technically difficult. The recurrence must be confirmed by biopsy and confined to the prostate, and the patient is told that in this role the method remains experimental and what the alternatives are.
Honestly put: in the German S3 guideline on prostate cancer, HIFU is not among the standard curative treatments, which are surgery, external radiotherapy and brachytherapy. The guideline finds the data on the effectiveness and safety of focal HIFU insufficient, and long-term results cannot yet be judged conclusively. It allows focal therapy only for a low-risk tumour in one half of the gland, in men who decline both standard treatment and active surveillance. HIFU is therefore offered after a thorough discussion of alternatives, ideally within studies or registries; the guideline authors explicitly favour registering HIFU patients.
HIFU for other tumours
For liver, pancreatic and kidney tumours and bone metastases, HIFU and MRI-guided focused ultrasound are used mostly for pain relief or local control in selected patients and in clinical studies, not as a replacement for surgery or systemic therapy; in kidney tumours the method is still experimental. Benign uterine fibroids are a separate gynaecological topic.
Other local ablation methods deliver energy differently. Radiofrequency and microwave ablation heat the tumour through a needle inserted through the skin. NanoKnife, or irreversible electroporation, destroys cells with electrical pulses instead of heat. The tumour board decides which method fits the tumour’s size and location.
Risks, limits and follow-up
The main risks of prostate HIFU concern urination and erections; many after-effects are temporary, but not all. The heat makes the prostate swell at first, so a urinary catheter stays in for about one to two weeks; otherwise urine may be retained. Burning on urination is common and usually temporary. Less often, incontinence, erectile dysfunction or a narrowing of the urethra follow.
Follow-up means regular PSA tests, MRI and, if needed, a repeat biopsy: the tumour can appear in untreated parts of the gland, and PSA alone cannot show this reliably. After focal therapy, the German guideline advises targeted and systematic biopsy at 6–12 months. Repeat HIFU, surgery or radiotherapy generally remain possible, but surgery after HIFU can be more difficult and the results may be worse – the patient should know this in advance.
Frequently asked questions
Can HIFU cure prostate cancer?
Cure is the aim, but there is no proof yet that results match surgery or radiotherapy, and patients must be told so beforehand. Studies with ten or more years of follow-up are lacking. If the tumour returns, a cure is usually still possible with radiotherapy or surgery, so follow-up checks matter as much as the procedure.
Will I stay continent and keep my erections after HIFU?
Nobody can promise that, but the chances are better if only part of the gland is treated. Focal therapy harms urination and potency much less often than whole-gland treatment; incontinence after it is very rare, erectile problems more common. Much depends on erectile function beforehand and on the zone treated. When HIFU treats a recurrence after radiotherapy, complications are more frequent.
Who is HIFU not suitable for?
Above all, men whose tumour has spread beyond the prostate: the German guideline advises against focal therapy with any technology for them. For high-risk cancer, the European Association of Urology recommends neither focal nor whole-gland treatment. In low-risk disease, active surveillance usually comes first. There are technical limits too: in a large prostate, ultrasound struggles to reach the front of the gland.
How long does HIFU take, and how long is the hospital stay?
The procedure usually takes 30 minutes to 3 hours, depending on how much tissue needs treating. Afterwards, men usually stay in hospital for 2–3 nights. The catheter remains for about one to two weeks, so agree the length of your stay in Germany with the hospital in advance.
How AlenMed arranges HIFU treatment in Germany
AlenMed starts with the documents: your PSA history, the multiparametric MRI of the prostate on disc, the biopsy report with the Gleason score, a grade of how aggressive the cells look under the microscope, and reports on previous treatment. We translate them and submit them to urologists at partner hospitals, who assess whether HIFU is suitable or a standard method is preferable.
If a urologist at home has already proposed a treatment and doubts remain, start with a second opinion. We arrange the visa invitation letter, an interpreter at consultations and, with the hospital, a plan for follow-up checks after you return home. The AlenMed office is in Munich; partner hospitals are across Germany. For an overview, see urology in Germany.
This material is for reference only and is not an offer. Whether HIFU suits you and which treatment to choose is decided by a doctor at an in-person consultation.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
